Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: A randomized-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 430-437

  Page, Stephanie T ^a   Lin, Daniel W ^b,c   Mostaghel, Elahe A ^a,c   Marck, Brett T ^d   Wright, Jonathan L ^b   Wu, Jennifer ^a   Amory, John K ^a   Nelson, Peter S ^a,c   Matsumoto, Alvin M ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; DOUBLE BLIND PROCEDURE; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROGENS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MICRODISSECTION; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN;

EID: 79951714359     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1865     Document Type: Article

References (36)

1. Beg S, Al-Khoury L, Cunningham GR 2008 Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes 15:364-370
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-731
3. Behre HM, Bohmeyer J, Nieschlag E 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 40:341-349 (Pubitemid 24194627)
4. Roddam AW, Allen NE, Appleby P, Key TJ 2008 Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-183 (Pubitemid 351480553)
5. Liverman C, Blazer, DG, eds 2003 Testosterone and Aging: clinical research directions. Institute of Medicine of the National Academies, Washington, DC, 2003
6. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD 1990 Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 595:53-66 (Pubitemid 20282939)
7. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS 2006 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351-2361 (Pubitemid 44749363)
8. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ 2006 Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850-3856 (Pubitemid 44536854)
9. Wilson JD 2001 The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 13:673-678 (Pubitemid 34240215)
10. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman Jr CA 2003 The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224 (Pubitemid 36859473)
11. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202
12. Norman RW, Coakes KE, Wright AS, Rittmaster RS 1993 Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 150:1736-1739 (Pubitemid 24346938)
13. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R 2008 Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72:808-812
14. Qoubaitary A, Swerdloff RS,Wang C 2005 Advances in malehormone substitution therapy. Expert Opin Pharmacother 6:1493-1506
15. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS 2002 The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 87:1467-1472 (Pubitemid 34615223)
16. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ 2001 A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078-4088 (Pubitemid 32848516)
17. Swerdloff RS, Wang C 1998 Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin Endocrinol Metab 12:501-506
18. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448
19. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT 1992 The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549-1557
20. Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, Marck BT, Bremner WJ, Amory JK 2010 Dose-dependent increase in intratesticular testosterone by very low dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. 2010 J Clin Endocrinol Metab 95:3806-3813
21. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454
22. Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res 70:1286-1295
23. Tusher VG, Tibshirani R, Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121 (Pubitemid 32397092)
24. Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR 2009 Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol 2:39-45
25. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ 1992 Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 147:810-814
26. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510 (Pubitemid 38269849)
27. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R 2003 AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88:2673-2681 (Pubitemid 36724441)
28. Wang C, Dobs A, Matsumoto A, Spark R, Redmond G, Weber T, Iranmanesh A, Schwartz S, Christenson P, Hull L, Swerdloff R 2004 Effects of long term transdermal administration of dihydrotestosterone (DHT) gel in older men. 12th International Congress of Endocrinology, Lisbon, Portugal, p OR119
29. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB 2007 The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf) 66:579-585 (Pubitemid 46434947)
30. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM 2009 Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 160:821-831
31. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS 2007 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041 (Pubitemid 46910214)
32. Marks LS, Mostaghel EA, Nelson PS 2008 Prostate tissue androgens: history and current clinical relevance. Urology 72:247-254
33. Luu-The V, Belanger A, Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22:207-221 (Pubitemid 351611954)
34. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451-1457 (Pubitemid 41798454)
35. Ellem SJ, Risbridger GP 2009 The dual, opposing roles of estrogen in the prostate. Ann NY Acad Sci 1155:174-186
36. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ 2009 Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 94:4785-4792